KRAS and Miyoshi myopathy: To the best of our knowledge, ours is the first study to use NGS to assess BRAF, NRAS and KRAS mutations in a large cohort of patients with MM (including primary and secondary leukemic forms) in the context of other clinical and biological features of the disease, and to determine a MAPK mutation-associated transcriptional signature in MM.